VISLISI trial, a prospective clinical study allowing identification of a new metalloprotease and putative virulence factor from Staphylococcus lugdunensis.
Fiche publication
Date publication
décembre 2016
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CIANFERANI Sarah, Pr MEYER Nicolas
Tous les auteurs :
Argemi X, Prévost G, Riegel P, Keller D, Meyer N, Baldeyrou M, Douiri N, Lefebvre N, Meghit K, Ronde Oustau C, Christmann D, Cianférani S, Strub JM, Hansmann Y
Lien Pubmed
Résumé
Staphylococcus lugdunensis is a coagulase-negative staphylococcus that displays an unusually high virulence rate close to that of Staphylococcus aureus. It also shares phenotypic properties with S. aureus and several studies found putative virulence factors. The objective of the study was to describe the clinical manifestations of S. lugdunensis infections and investigate putative virulence factors.
Référence
Clin. Microbiol. Infect.. 2016 Dec;: